Relmada Therapeutics (RLMD) EPS (Basic) (2012 - 2026)
Relmada Therapeutics (RLMD) posted quarterly EPS (Basic) of -$0.65 for Q1 2026, down 11.16% year-over-year from -$0.73 in Q1 2025, and down 28.81% quarter-over-quarter from -$0.51 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) EPS (Basic) (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported EPS (Basic) for 15 consecutive years, with -$0.65 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 11.16% year-over-year to -$0.65; the TTM figure through Mar 2026 stood at -$1.11 (up 56.18% YoY), while the FY2025 annual figure was -$1.64, up 38.67% from the prior year.
- EPS (Basic) eased to -$0.65 in Q1 2026 per RLMD's latest filing, from -$0.51 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.3 in Q2 2025 and bottomed at -$2.85 in Q1 2022.
- Historically, EPS (Basic) has averaged -$0.93 across 5 years, with a median of -$0.75 in 2024.
- Annual changes were most pronounced in 2022 — EPS (Basic) sank 110.43% — and 2023, when it soared 68.54%.
- Relmada Therapeutics' EPS (Basic) stood at -$1.32 in 2022, then soared by 35.6% to -$0.85 in 2023, then rose by 28.07% to -$0.61 in 2024, then rose by 17.29% to -$0.51 in 2025, then fell by 28.81% to -$0.65 in 2026.
- Business Quant data shows RLMD's EPS (Basic) at -$0.65 in Q1 2026, -$0.51 in Q4 2025, and -$0.3 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -0.11 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.11 |
| Mar 31, 2026 | -0.21 |
| Dec 31, 2025 | -0.51 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.30 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -0.61 |
| Sep 30, 2024 | -0.73 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.73 |
| Dec 31, 2023 | -0.85 |
| Sep 30, 2023 | -0.71 |
| Jun 30, 2023 | -0.82 |
| Mar 31, 2023 | -0.90 |
| Dec 31, 2022 | -1.31 |
| Sep 30, 2022 | -1.29 |
| Jun 30, 2022 | -1.52 |
| Mar 31, 2022 | -2.18 |
| Dec 31, 2021 | -1.95 |
| Sep 30, 2021 | -2.44 |